Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Latest From LG Chem, Ltd.

Biocon Buoyant On ‘Unique Positioning’ Of Partnered COVID-19 Antibody

Biocon management signals the potential of its partnered entry with Serum Institute and Adagio Therapeutics into the communicable diseases segment. Continuing large supply opportunities for COVID-19 vaccines and prospects for boosters, alongside the promising profile of the neutralizing antibody being developed by its US-based partner, also bode well.

Commercial Coronavirus COVID-19

Lenzilumab & Evusheld Make It Onto EU List Of ‘Most Promising’ COVID-19 Treatments

Two products that were on the European Commission’s original list of the “top five” COVID-19 candidate therapeutics in development have been dropped from the latest “top 10” portfolio.

Europe Coronavirus COVID-19

Coronavirus Update: Brii Files US EUA For Antibody Combo

Chinese venture Brii seeks US emergency authorization for its antibody combo, as Chugai aims for wider use of its antibody cocktail in Japan and two other Chinese firms link up on an oral antiviral. 

Coronavirus COVID-19 Biologics

Coronavirus Update: Japan Approves Sotrovimab

Japan approves a second antibody therapy for COVID-19 in short order, while India gives the go-ahead to a local clinical program for Novavax/Serum Institute's recombinant protein vaccine candidate. 

Coronavirus COVID-19 Approvals
See All

Company Information

  • Industry
  • Medical Devices
  • Pharmaceuticals
    • Vaccines
  • Other Names / Subsidiaries
    • LG LI
UsernamePublicRestriction

Register